Cell and Gene Therapy CDMO Landscape
The global cell and gene therapy CDMO market, valued at approximately $7 billion in 2024, is projected to exceed $74 billion by 2034 at a 28% CAGR. Over 135 specialized CDMOs now operate worldwide, up from a handful a decade ago, driven by the surge in FDA-approved advanced therapies and a growing clinical pipeline exceeding 3,000 active trials.
Geographic Distribution
The United States leads with 34 CGT-focused CDMOs, followed by China (20) and the United Kingdom (11). Key manufacturing clusters have formed around:
| Region | Notable Hubs | Specialization |
|---|---|---|
| North America | Maryland, Texas, Massachusetts, California | AAV vectors, CAR-T commercial manufacturing |
| Europe | Oxford, Edinburgh, Munich, Hillerød | Lentiviral vectors, allogeneic cell therapy |
| Asia-Pacific | Yokohama, Guangzhou, Incheon | iPSC-derived therapies, process development |
Key Capability Segments
- Viral Vector Manufacturing
- AAV and lentiviral vectors dominate, with leading CDMOs operating bioreactors up to 2,000L scale. Lonza, Catalent, and Oxford Biomedica hold significant commercial-approved capacity.
- Cell Therapy Processing
- Both autologous (patient-specific) and allogeneic (donor-derived) manufacturing. CAR-T cell therapies drive the majority of demand, with iPSC-based therapies emerging as a high-growth segment.
- Plasmid DNA Production
- Critical upstream supply for viral vector manufacturing. Dedicated pDNA facilities from Thermo Fisher (Carlsbad, CA) and Charles River (Keele, UK) address a key bottleneck.
Industry Trends
Major consolidation is reshaping the landscape. Novo Holdings’ acquisition of Catalent and the merger of Minaris Regenerative Medicine with WuXi Advanced Therapies’ US/UK operations signal a shift toward vertically integrated, multi-continent platforms. Approximately 45% of facilities have adopted automation to address persistent workforce and vein-to-vein logistics challenges.
For therapy sponsors evaluating CDMOs, critical selection factors include regulatory track record (FDA/EMA commercial approvals), technology transfer expertise, scale-out vs. scale-up capability, and supply chain redundancy across geographies.